William Blair Maintains Neurogene(NGNE.US) With Buy Rating
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook
Buy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401
Buy Rating for Neurogene Based on Strong Clinical Prospects and Technological Advantages
Neurogene Analyst Ratings
Buy Rating Affirmed for Neurogene Amid Promising Clinical Trials and Strategic FDA Milestones
Neurogene Secures RMAT Designation and Joins FDA START Program, Analyst Maintains Buy Rating
Buy Rating on Neurogene's Stock: RMAT Designation and Promising Clinical Prospects for NGN-401
Leerink Partners Sticks to Its Buy Rating for Neurogene (NGNE)
Neurogene Analyst Ratings
BMO Capital Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $65
Neurogene Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $51 Price Target
Neurogene Analyst Ratings
Neurogene Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $51 Price Target
Taysha Gene Therapies Upgraded at Jefferies on Rett Syndrome Asset